Goldman Sachs found itself on the opposite side of the deal table to GSK this week, but the bank’s presence will have been felt by the pharmaceuticals giant nonetheless.

GSK is selling its cancer business to Swiss peer Novartis for around $16 billion. As part of the deal, GSK will buy Novartis' vaccines division for roughly $7.1 billion and the two pharmaceutical groups will combine their consumer healthcare units.